Transurethral electrovaporization of the prostate

One-year experience

Steven A. Kaplan, Richard P. Santarosa, Alexis E. Te, Claus Roehrborn

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Objectives. To determine the safety and efficacy of transurethral electrovaporization of the prostate (TVP) in men with lower urinary tract symptoms. Methods. A prospective trial of 114 consecutive patients who underwent TVP since August 1994 was conducted. The mean follow-up period was 12.3 months. Parameters evaluated included American Urological Association symptom score (Sx), peak urinary flow rate (Qmax), operative time, postoperative catheterization time, length of hospital stay, and loss of days from work. Results. Of the 109 men available for follow-up, Sx decreased from 16.7 to 7.3, 6.5, 6.3, and 5.4 at 3, 6, 12, and 18 months, respectively (P <0.001), whereas Qmax increased from 7.9 to 14.8, 15.6, 16.7, and 16.5 mL/s at 3, 6, 12, and 18 months, respectively (P < 0.001). Mean catheterization time was 10.4 hours; mean hospital period was 0.9 days, and average loss of days from work was 5.6. Complications included intermittent postoperative hematuria in 65 patients (57%), clot retention in 6 (5%), and bulbar urethral stricture in 2 (2%). Of 74 men who were potent preoperatively, none had postoperative erectile dysfunction; retrograde ejaculation was noted in 62 (84%). Significant postoperative irritative symptoms were reported in 10 men (9%). Conclusions. On the basis of 1-year follow-up data, this study demonstrates that TVP is a safe and effective modality for treating lower urinary tract symptoms. However, longer, prospective, blinded studies are needed to determine efficacy relative to transurethral resection of the prostate.

Original languageEnglish (US)
Pages (from-to)876-881
Number of pages6
JournalUrology
Volume48
Issue number6
DOIs
StatePublished - Dec 1996

Fingerprint

Transurethral Resection of Prostate
Lower Urinary Tract Symptoms
Catheterization
Length of Stay
Urethral Stricture
Ejaculation
Hematuria
Erectile Dysfunction
Operative Time
Prospective Studies
Safety

ASJC Scopus subject areas

  • Urology

Cite this

Transurethral electrovaporization of the prostate : One-year experience. / Kaplan, Steven A.; Santarosa, Richard P.; Te, Alexis E.; Roehrborn, Claus.

In: Urology, Vol. 48, No. 6, 12.1996, p. 876-881.

Research output: Contribution to journalArticle

Kaplan, Steven A. ; Santarosa, Richard P. ; Te, Alexis E. ; Roehrborn, Claus. / Transurethral electrovaporization of the prostate : One-year experience. In: Urology. 1996 ; Vol. 48, No. 6. pp. 876-881.
@article{c1dfd4b6a7aa441490dbacfa9e0f2d5e,
title = "Transurethral electrovaporization of the prostate: One-year experience",
abstract = "Objectives. To determine the safety and efficacy of transurethral electrovaporization of the prostate (TVP) in men with lower urinary tract symptoms. Methods. A prospective trial of 114 consecutive patients who underwent TVP since August 1994 was conducted. The mean follow-up period was 12.3 months. Parameters evaluated included American Urological Association symptom score (Sx), peak urinary flow rate (Qmax), operative time, postoperative catheterization time, length of hospital stay, and loss of days from work. Results. Of the 109 men available for follow-up, Sx decreased from 16.7 to 7.3, 6.5, 6.3, and 5.4 at 3, 6, 12, and 18 months, respectively (P <0.001), whereas Qmax increased from 7.9 to 14.8, 15.6, 16.7, and 16.5 mL/s at 3, 6, 12, and 18 months, respectively (P < 0.001). Mean catheterization time was 10.4 hours; mean hospital period was 0.9 days, and average loss of days from work was 5.6. Complications included intermittent postoperative hematuria in 65 patients (57{\%}), clot retention in 6 (5{\%}), and bulbar urethral stricture in 2 (2{\%}). Of 74 men who were potent preoperatively, none had postoperative erectile dysfunction; retrograde ejaculation was noted in 62 (84{\%}). Significant postoperative irritative symptoms were reported in 10 men (9{\%}). Conclusions. On the basis of 1-year follow-up data, this study demonstrates that TVP is a safe and effective modality for treating lower urinary tract symptoms. However, longer, prospective, blinded studies are needed to determine efficacy relative to transurethral resection of the prostate.",
author = "Kaplan, {Steven A.} and Santarosa, {Richard P.} and Te, {Alexis E.} and Claus Roehrborn",
year = "1996",
month = "12",
doi = "10.1016/S0090-4295(96)00487-6",
language = "English (US)",
volume = "48",
pages = "876--881",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Transurethral electrovaporization of the prostate

T2 - One-year experience

AU - Kaplan, Steven A.

AU - Santarosa, Richard P.

AU - Te, Alexis E.

AU - Roehrborn, Claus

PY - 1996/12

Y1 - 1996/12

N2 - Objectives. To determine the safety and efficacy of transurethral electrovaporization of the prostate (TVP) in men with lower urinary tract symptoms. Methods. A prospective trial of 114 consecutive patients who underwent TVP since August 1994 was conducted. The mean follow-up period was 12.3 months. Parameters evaluated included American Urological Association symptom score (Sx), peak urinary flow rate (Qmax), operative time, postoperative catheterization time, length of hospital stay, and loss of days from work. Results. Of the 109 men available for follow-up, Sx decreased from 16.7 to 7.3, 6.5, 6.3, and 5.4 at 3, 6, 12, and 18 months, respectively (P <0.001), whereas Qmax increased from 7.9 to 14.8, 15.6, 16.7, and 16.5 mL/s at 3, 6, 12, and 18 months, respectively (P < 0.001). Mean catheterization time was 10.4 hours; mean hospital period was 0.9 days, and average loss of days from work was 5.6. Complications included intermittent postoperative hematuria in 65 patients (57%), clot retention in 6 (5%), and bulbar urethral stricture in 2 (2%). Of 74 men who were potent preoperatively, none had postoperative erectile dysfunction; retrograde ejaculation was noted in 62 (84%). Significant postoperative irritative symptoms were reported in 10 men (9%). Conclusions. On the basis of 1-year follow-up data, this study demonstrates that TVP is a safe and effective modality for treating lower urinary tract symptoms. However, longer, prospective, blinded studies are needed to determine efficacy relative to transurethral resection of the prostate.

AB - Objectives. To determine the safety and efficacy of transurethral electrovaporization of the prostate (TVP) in men with lower urinary tract symptoms. Methods. A prospective trial of 114 consecutive patients who underwent TVP since August 1994 was conducted. The mean follow-up period was 12.3 months. Parameters evaluated included American Urological Association symptom score (Sx), peak urinary flow rate (Qmax), operative time, postoperative catheterization time, length of hospital stay, and loss of days from work. Results. Of the 109 men available for follow-up, Sx decreased from 16.7 to 7.3, 6.5, 6.3, and 5.4 at 3, 6, 12, and 18 months, respectively (P <0.001), whereas Qmax increased from 7.9 to 14.8, 15.6, 16.7, and 16.5 mL/s at 3, 6, 12, and 18 months, respectively (P < 0.001). Mean catheterization time was 10.4 hours; mean hospital period was 0.9 days, and average loss of days from work was 5.6. Complications included intermittent postoperative hematuria in 65 patients (57%), clot retention in 6 (5%), and bulbar urethral stricture in 2 (2%). Of 74 men who were potent preoperatively, none had postoperative erectile dysfunction; retrograde ejaculation was noted in 62 (84%). Significant postoperative irritative symptoms were reported in 10 men (9%). Conclusions. On the basis of 1-year follow-up data, this study demonstrates that TVP is a safe and effective modality for treating lower urinary tract symptoms. However, longer, prospective, blinded studies are needed to determine efficacy relative to transurethral resection of the prostate.

UR - http://www.scopus.com/inward/record.url?scp=0030453750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030453750&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(96)00487-6

DO - 10.1016/S0090-4295(96)00487-6

M3 - Article

VL - 48

SP - 876

EP - 881

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6

ER -